PsiOxus Therapeutics PsiOxus - a great place to work - PsiOxus Therapeutics

Home
Contact

PsiOxus – a great place to work!

Comments are closed.

Sign up to our mailing list

Mailing list sign up

Email *

Vision & Strategy

Vision & Strategy

We aim to lead the world in tumor re-engineering.

Technology & Products

T-SIGn Product Platform

View our T-Sign technology here.

T-SIGn Pipeline

T-SIGn Pipeline

View information on our clinical trials here.

People & Investors

Our People

PsiOxus brings together highly experienced management and investors.

Latest News & Events

PsiOxus to Present Positive Biomarker Data at ESMO 2021 Demonstrating the Potential of Their Novel Tumor-Selective T SIGn® vector, NG-350A, to Re-Engineer Advanced Cancers

14th September 2021

PsiOxus and bluebird bio Present Novel Data Combining PsiOxus T-SIGn Platform with CAR-T Therapy to Clear Primary Tumors and Metastases

14th April 2021

PsiOxus Therapeutics updates agreement with Bristol-Myers Squibb to advance their clinical stage immuno-oncology collaboration

6th April 2021

logo

Email
Links
Sitemap
Privacy Policy

Copyright

Designed and Produced by www.imageworks.co.uk
© Copyright 2019 PsiOxus Therapeutics

© Copyright 2022 PsiOxus Therapeutics

RSS

About
Vision & Strategy
Our People
T-SIGn Platform Technology
- Pipeline
- Publications and Posters
Partners and Investors
News and Events
Careers
Contact Us

Responsive Menu Pro Image

Responsive Menu Clicked Image

Menu